Richard J. Jones

Richard J. Jones

Auto-generated profile, based on publicly available information

Richard J. Jones

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and the Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2015 in Blood
Verified
Journal Article
Open access
PDF file
SMShannon R. McCurdy
Shannon R. McCurdy
JKJennifer A. Kanakry
Jennifer A. Kanakry
MSMargaret M. Showel
Margaret M. Showel
HTHua-Ling Tsai
Hua-Ling Tsai
JBJavier Bolaños-Meade
Javier Bolaños-Meade
YKYvette L. Kasamon
Yvette L. Kasamon
Key Points: Nonmyeloablative, related HLA-haploidentical BMT utilizing high-dose posttransplantation cyclophosphamide has a favorable safety profile. Risk-stratified relapse and survival outcomes with this approach are comparable to those of HLA-matched BMT.

1 October 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YKYvette L. Kasamon
Yvette L. Kasamon
JBJavier Bolaños-Meade
Javier Bolaños-Meade
GPGabrielle T. Prince
Gabrielle T. Prince
HTHua-Ling Tsai
Hua-Ling Tsai
SMShannon R. McCurdy
Shannon R. McCurdy
RJRichard J. Jones
Richard J. Jones
Purpose: Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated the effect of age on NMA haplo-BMT outcomes in patients age 50 to 75 years.Patients and Methods: A retrospective analysis was performed of 271 consecutive patients with hematologic malignancies, age 50 to 75 years, who received NMA, T-cell–replete haplo-BMT with high-dose post-transplantation cyclophosphamide.Results: The median age was 61 years, with 115 patients (42%) age 50 to 59, 129 (48%) age 60 to 69, and 27 (10%) age 70 to 75 years. Overall, 84% of patients had intermediate- or high-/very high–risk disease. The 6-month probabilities of grade 3 or 4 acute graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) were 3% and 8%, respectively. Patients in their 50s, 60s, and 70s had 6-month NRM probabilities of 8%, 9%, and 7%, respectively (P = .20). With a median follow-up of 4 years, corresponding 3-year progression-free survival probabilities were 39%, 35%, and 33% (P = .65), and corresponding 3-year overall survival probabilities were 48%, 45%, and 44% (P = .66). Three-year progression-free survival probabilities were 40% in acute myeloid leukemia (n = 65), 39% in aggressive non-Hodgkin lymphoma (n = 83), and 37% in indolent or mantle-cell lymphoma (n = 65). Older patient age was associated with a significantly higher risk of grade 2 to 4 acute GVHD but not grade 3 to 4 acute or chronic GVHD. No statistically significant associations were found between older age (relative to age 50 to 59 years or as a continuous variable) and NRM, relapse, or survival.Conclusion: NMA haplo-BMT with post-transplantation cyclophosphamide has encouraging safety and survival outcomes in patients age 50 to 75 years. In patients otherwise fit for BMT, the results support consideration of this approach despite advanced age.

4 June 2009 in Blood
Verified
Journal Article
Open access
PDF file
RJRichard J. Jones
Richard J. Jones
CGChristopher D. Gocke
Christopher D. Gocke
YKYvette L. Kasamon
Yvette L. Kasamon
CMCarole B. Miller
Carole B. Miller
BPBrandy Perkins
Brandy Perkins
WMWilliam Matsui
William Matsui
Although Hodgkin and Reed-Sternberg (HRS) cells are B lymphoid cells, they are unlike any normal cells of that lineage. Moreover, the limited proliferative potential of HRS cells belies the clinical aggressiveness of Hodgkin lymphoma (HL). More than 20 years ago, the L428 HL cell line was reported to contain a small population of phenotypic B cells that appeared responsible for the continued generation of HRS cells. This observation, however, has never been corroborated, and such clonotypic B cells have never been documented in HL patients. We found that both the L428 and KM-H2 HL cell lines contained rare B-cell subpopulations responsible for the generation and maintenance of the predominant HRS cell population. The B cells within the HL cell lines expressed immunoglobulin light chain, the memory B-cell antigen CD27, and the stem cell marker aldehyde dehydrogenase (ALDH). Clonal CD27+ALDHhigh B cells, sharing immunoglobulin gene rearrangements with lymph node HRS cells, were also detected in the blood of most newly diagnosed HL patients regardless of stage. Although the clinical significance of circulating clonotypic B cells in HL remains unclear, these data suggest they may be the initiating cells for HL.

20 April 2004 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
RJRichard J. Jones
Richard J. Jones
WMWilliam Matsui
William Matsui
BSB. Douglas Smith
B. Douglas Smith
Most conventional anticancer agents are nonselective cellular poisons with broad activities against most dividing cells, regardless of whether they are malignant or not; any preferential effects of these agents on cancer cells usually reflect their relatively high rates of cell division. The widely acclaimed success of imatinib mesylate (also known as STI571 or Gleevec, and herein referred to as imatinib) in chronic myeloid leukemia (CML) highlights the enormous possibilities that the development of drugs directed against cancer-specific targets has for improving cancer treatment. Targeted anticancer agents have the potential to favorably influence patient survival by decreasing toxicity and improving disease control. However, recent laboratory and clinical data raise questions about whether new anticancer agents will effectively target relevant subsets of cancer cells. These issues have implications for interpreting results of clinical studies with targeted therapies as well as for the future development of new anticancer treatments.

16 September 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
GGGabriel Ghiaur
Gabriel Ghiaur
SYSrinivasan Yegnasubramanian
Srinivasan Yegnasubramanian
BPBrandy Perkins
Brandy Perkins
JGJessica L. Gucwa
Jessica L. Gucwa
JGJonathan M. Gerber
Jonathan M. Gerber
RJRichard J. Jones
Richard J. Jones
The high expression of aldehyde dehydrogenase 1, also known as retinaldehyde dehydrogenase, by hematopoietic stem cells (HSCs) suggests an important role for retinoic acid (RA) signaling in determining the fate of these cells. We found that primitive human bone marrow-derived CD34+CD38− cells not only highly express aldehyde dehydrogenase 1, but also the RA receptor α. Despite the up-regulation of early components of RA signaling, the downstream pathway remained inactive in the primitive CD34+CD38− cells. Primitive hematopoietic cells rapidly undergo terminal differentiation when cultured away from their microenvironment; however, we found that inhibition of RA signaling maintained their primitive phenotype and function, and promoted their self-renewal. HSCs reside in a complex microenvironment that enforces the balance between self-renewal and differentiation. The exact physiologic mechanisms by which the niche controls HSC fate remain elusive. The embryonic gonadal microenvironment has recently been shown to determine germ-cell fate by degrading RA through expression of the P450 retinoid-inactivating enzyme CYP26B1. We found that the bone marrow microenvironment similarly can control primitive hematopoietic cell fate via modulation of retinoid bioavailability. Accordingly, we found that bone marrow stromal cell CYP26 was also able to inactivate retinoids in serum, preventing RA signaling. Thus, primitive hematopoietic cells appear to be intrinsically programmed to undergo RA-mediated differentiation unless prevented from doing so by bone marrow niche CYP26. Modulation of RA signaling also holds promise for clinical HSC expansion, a prerequisite for the wide-scale use of these cells in regenerative medicine and gene therapy.

4 July 2005 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GAGreg R. Angstreich
Greg R. Angstreich
WMWilliam Matsui
William Matsui
CHCarol Ann Huff
Carol Ann Huff
MVMilada S. Vala
Milada S. Vala
JBJames Barber
James Barber
RJRichard J. Jones
Richard J. Jones